Partnering to Eliminate HIV/AIDS
In Africa, HIV/AIDS disproportionately affects women, increasing the risk of mother-to-child transmission of the disease and threatening communities. In response, Chevron has made eliminating mother-to-child transmission of HIV in Angola, Nigeria and South Africa one of our priorities.
We partner with governments and global, national and local organizations to strengthen health systems, create greater HIV/AIDS awareness, reduce the stigma associated with the disease, and provide access to testing and treatment.
Preventing Mother-to-Child Transmission of HIV
In Angola and Nigeria, our voluntary workplace program to prevent mother-to-child transmission (PMTCT) of HIV creates a culture that encourages HIV testing and treatment, fights the stigma associated with the disease, and provides comprehensive medical care for employees and their dependents. The program has had a remarkable impact. Since 2001 in Nigeria and 2005 in Angola, Chevron has received no reports of mother-to-child transmission of HIV among its employees or qualified dependents participating in PMCTC programs.
To expand on our success and have a greater impact within the communities in which we operate, Chevron joined UNAIDS, the U.S. President's Emergency Plan for AIDS Relief and other leading world groups to help eliminate mother-to-child transmission of HIV. In 2012, we launched new partnerships with Pact, Born Free Africa (BFA), and The Global Fund to Fight AIDS, Tuberculosis and Malaria. Working together with these partners as well as with national and local governments, we can help eliminate mother-to-child transmission of HIV in Angola, Nigeria and South Africa.
In 2012, Chevron and BFA collaborated on an ambitious program to empower the Nigerian federal and state governments to lead their own HIV responses, setting concrete targets to reduce HIV transmission and develop an achievable plan. By working with members of the Nigerian government and the international donor community, as well as local implementing partners, this investment is increasing services for the prevention of mother-to-child transmission of HIV in the states that are most affected. Chevron initially supported a pilot program in Nasarawa State and has since expanded the partnership to Bayelsa and Rivers states.
Since its launch in 2012, our partnership with BFA in Nigeria has contributed to a dramatic increase in PMTCT programs in Nigeria and to impressive results in the states where we work. In Nasarawa, Bayelsa and Rivers states:
- 670 health clinics are now providing PMTCT services.
- 220,077 pregnant women have been tested for HIV; 4.4 percent tested positive.
- 7,425 pregnant women living with HIV have been initiated onto antiretroviral medications.
Through our partnership with Pact and the PROMOT Project in Bayelsa State, we have established a sustainable, statewide, community-based, government-supported PMTCT outreach program. Since our partnership began in 2012, PROMOT has achieved these remarkable results:
- Training in state-of-the-art PMTCT approaches and techniques has been provided to 624 people.
- PMTCT messaging has reached 185,286 people.
- More than 46,000 pregnant women have taken HIV tests, received their results and been counseled at health facilities.
The Global Fund to Fight AIDS, Tuberculosis and Malaria
Since 2008, Chevron has partnered with The Global Fund to Fight AIDS, Tuberculosis and Malaria, directing $60 million to programs in Angola, Nigeria, South Africa, Indonesia, Thailand, Vietnam and the Philippines.
Chevron is The Global Fund's inaugural Corporate Champion and one of its largest single corporate partners. Chevron's support of The Global Fund has contributed to saving 9.6 million lives.
Providing Pediatric Health Care
We also partner with Baylor College of Medicine and the Baylor International Pediatric AIDS Initiative (BIPAI) at Texas Children's Hospital, the largest university-based program in the world dedicated to improving the lives of HIV-infected children. BIPAI's Global Health Corps program provides life-saving pediatric health care, treatment and training to the most medically underserved populations in Africa and Latin America. The program places physicians in these underserved communities to deliver direct care and treatment to patients and to provide health training to local medical professionals.
Fighting Sickle Cell Anemia
Chevron partnered with the Republic of Angola, Baylor College of Medicine and Texas Children's Hospital in 2011 to create Angola's first comprehensive program to screen and treat newborns for sickle cell anemia. Sickle cell disease is an inherited disorder that causes susceptibility to infection, hemolytic anemia, sporadic blockage of blood vessels and organ damage. In Africa, no universal screening program for newborns exists. At the beginning of our partnership in 2011, Chevron pledged $4 million to the Angola Sickle Cell Initiative. In 2015, we committed an additional $5 million to this initiative over the next five years.
Since the program started in 2011, more than 96,000 babies have been tested for sickle cell anemia, and more than 500 Angolan nurses, lab technicians and social workers have been trained.
Chevron has expanded our partnership with Texas Children's Hospital (TCH) and Baylor College of Medicine (BCM) to improve the quality of health care in rural Colombia. This successful partnership has helped improve and increase access to health care in Liberia, Angola and Romania since 2011. Our latest collaboration focuses on members of the Wayúu indigenous community in La Guajira, Colombia, one of the country's most impoverished states. The $1.5 million, five-year pediatric health care program called SAIL (Salud y Autosuficiencia Indígenas en La Guajira) aims to decrease the high morbidity and mortality rates for children and mothers in this remote area. Chevron has been producing natural gas in the area for nearly 40 years.
Chevron has partnered with the Desmond Tutu HIV Foundation to fund the Kethuphila Youth Centre in Masiphumelele (Masi), a township outside the Cape Town city center. It provides youth-friendly health services in addition to facilities for recreation and study. Through the partnership, we are reaching out to the 900 students at the Masi high school and encouraging them to register for activities at the center. The objective is to address high-risk sexual behavior, concerns around HIV testing, the lack of youth-friendly services and feelings of vulnerability among the youth.
In 2012, Chevron partnered with the Path2Health Foundation on a project called Empowering People Living with HIV/AIDS (PHA) to Promote Adolescent Sexual Health through Parent-Child Communication. The project strengthened PHA networks in the Sisaket, Ubonratchathani and Udornthani provinces. PHA groups became community leaders, training parents to improve their family communication skills about sex so that their children protect themselves from sexually transmitted infections and unplanned pregnancies.
East Kalimantan and Riau, Indonesia
In Indonesia, we worked in partnership with Jhpiego and local government agencies to improve maternal and newborn health services in communities surrounding Chevron's production area in East Kalimantan Province and in Riau Province. During this two-year project, which started in January 2011, we developed a model for improving the quality of and increasing access to midwife services to ensure that all pregnant women and newborns are afforded skilled care before, during and after delivery. The project includes a series of training sessions for midwives in infection prevention, normal delivery care, basic emergency obstetrics and newborn care. We also established Desa SIAGA, or the Alert Village initiative, which advocates everyone playing a part in helping to save mothers' lives. SIAGA stands for SIap (ready), Antar (take, transport), jaGA (stand by or guard).
Chevron partnered with the Lagos University Teaching Hospital to fund a molecular biology research laboratory. The lab provides genetic diagnostic tools that aid in the diagnosis, management and treatment of people with genetic abnormalities. In July 2014, the laboratory helped detect the first case of the Ebola virus in Nigeria.